Searle/Pfizer Celebrex Label Should Include GI Superiority To NSAIDs - Cmte.
Executive Summary
Clinical and surrogate marker data demonstrating superiority of Searle/Pfizer's Celebrex to other non-steroidal anti-inflammatory drugs in gastrointestinal complications should be included in labeling, FDA's Arthritis Advisory Committee recommended Dec. 1.